Lupus therapy

Wallace DJ, Hahn BH (eds) (1993) Dubois' lupus erythematosus, 4th edn. Lea & Febiger, PhiladelphiaGoogle Scholar

Lahita RG (1992) Syatemic lupus erythematosus, 2nd edn. Churchill Livingstone, New YorkGoogle Scholar

Baart de la Faille H, Kater L (1994) Lupus erythematosus. In: Kater L, Baart de la Faille H (eds) Dermatological and internal aspects of systemic autoimmune diseases: an integrated approach. Elsevier, Amsterdam, in the pressPubMedGoogle Scholar

Tan EM, Cohen AS, Fries J et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271–1277PubMedGoogle Scholar

Broby-Johansen U, Kristensen JK (1989) Antipsoriatic effect of local corticosteroids-O₂ consumption and blood flow measurements compared to clinical parameters. Clin Exp Dermatol 14: 137–140Google Scholar

Weelden H van, Velthuis PJ, Baart de la Faille H (1989) Light-induced skin lesions in lupus erythematosus: photobiological studies. Arch Dermatol Res 282: 470–474Google Scholar

Velthuis PJ, Weelden H van, Baart de la Faille H (1990) Immunohistochemistry of light-induced skin lesions in lupus erythematosus. Acta Derm Venereol (Stockholm) 70: 93–98Google Scholar

Callen JP (1985) Systemic lupus erythematosus in patients with chronic cutaneous (discoid) lupus erythematosus. J Am Acad Dermatol 12: 278–288Google Scholar

Sontheimer RD, Thomas JR, Gilliam JN (1979) Subacute cutaneous-lupus erythematosus. A cutaneous marker for a distinct lupus-erythematosus subset. Arch Dermatol 115: 1409–1415Google Scholar

Dubois EL (1978) Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthr Rheum 8: 33–51Google Scholar

Williams HJ (1991) for the cooperative systematic studies of rheumatic diseases. Comparison of hydroxychloroquine and placebo in the treatment of lupus arthritis. Arthritis Rheum [Suppl 1] 34: 186Google Scholar

Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloquine sulfate in systemic lupus erythematosus. New Engl J Med 324: 150–154Google Scholar

Kater L, Baart de la Faille H, Talal N (1994) Guidelines for the therapy of autoimmune diseases. In: Kater L, Baart de la Faille H (eds) Dermatological and internal aspects of systemic autoimmune diseases: an integrated approach. Elsevier, Amsterdam (in press)Google Scholar

Austin HA, Klippel JH, Balow JE et al. (1986) Therapy of lups nephritis. Controlled trial of prednisone and cytotoxic drugs. New Engl J Med 314: 614–619Google Scholar

Boumpas DT, Austin HA III, Vaughn EM, et al. (1992) Controlled trial of pulse methyl-prednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741–745CrossRefPubMedGoogle Scholar

Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients wiht lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only Arthritis Rheum 34: 945–950Google Scholar

Derksen RHWM, Hené RJ, Kater L (1992) The long-term clinical outcome of 56 patients with biopsy proven lupus nephritis followed at a single center. Lupus 1: 97–103Google Scholar

Haga HJ, D'Cruz D, Asherson R, Hughes GRV (1992) Short term effect of weekly intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 51: 885–888PubMedGoogle Scholar

Quismorio FP (1993) Cardiac abnormalities in systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Lea & Febiger, Philadelphia, pp 332–342Google Scholar

Quismorio FP (1988) Clinical and pathologic features of lung involvement in systemic lupus erythematosus. Semin Respir Dis 9: 297–304Google Scholar

Priofsky B (1975) Immune haemolytic disease: the autoimmune haemolytic anemias. Clin Haematol 4: 167–180Google Scholar

Derksen RHWM, Groot de PG, Kater L, Nieuwenhuis HK (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment. Ann Rheum Dis 52: 689–692Google Scholar

Thomson AW, Nield GH (1991) Cyclosporine: use outside transplantation. Br Med J 302: 4–5Google Scholar

Miescher PA, Favre H, Mihatsch MJ, Chatelanat F, Huang YP, Zubler R (1988) The place of cyclosporin A in the treatment of connective tissue diseases. Transplant Proc [suppl 4]: 22: 224–237Google Scholar

Radhakrishnan J, Kunis CL, D'Agati V, Appel GB (1992) Cyclosporine treatment of lupus membranous nephropathy. J Am Soc Nephrol 3: 317Google Scholar

Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H (1993) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychyloroquine. Br J Dermatol 127: 513–518Google Scholar

Holm AL, Bowers KE, McMeekin TO, Gaspari AA (1993) Chronic cutaneous lupus erythematosus treated with thalidomide. Arch Dermatol 129: 1548–1550Google Scholar

Coburn PR, Shuster S (1982) Dapsone and discoid lupus erythematosus. Br J Dermatol 106: 105–106Google Scholar

Walton AJE, Snaith ML, Locniskar M, Cumberland AG, Morrow WJW, Isenburg DA (1991) Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 50: 463–1166Google Scholar

Dwyer JM (1992) Manipulating the immune system with immune globulin. New Engl J Med 326: 107–116Google Scholar

NIH Consensus Development Conference (1990) Intravenous immune globulin: prevention and treatment of disease. Consensus statement, May 21–23, vol 8, no 5. Department of Health and Humane Services, BethesdaGoogle Scholar

Imbach P, Barundun S, D'Appuzo V et al (1981) High-dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1: 1228–1231Google Scholar

Borg EJ ter, Kallerberg CGM (1992) Treatment of severe thrombocytonpenia in systemic lupus erythematosus with intravenous gammaglobulin. Ann Rheum Dis 51: 1149–1151Google Scholar

Maier WP, Gordon DS, Howard RF et al (1990) Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 33: 1233–1239Google Scholar

Majer RV, Hyde RD (1988) High dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anemia. Clin Lab Haematol 10: 391–395Google Scholar

Jordan SC (1989) Intravenous gamma-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 53: S164-S169Google Scholar

Pirner K, Rubbert A, Burmester GR, Kalden JR, Manger B (1993) Intravenös verabreichte Immunglobuline beim systemischen Lupus erythematodes. Infusionsther Transfusionsmed 20 [Suppl 1]: 131–136Google Scholar

Vezon G, Reiffers J, Serroni-Vivien JF et al (1985) Plasma exchange in autoimmune thrombocytopenic purpura: comparative study with intravenous injections of gamma globulin. Plasma Ther Transfusion Technol 6: 565–570Google Scholar

French Cooperative Study Group (1985) A randomized trial of plasma exchange in severe acute systemic lupus erythematosus. Plasma Ther Transfusion Technol 6: 535–539Google Scholar

Derksen RHAW, Hené RJ, KallerbergCG, Valentijn RM, Kater L (1988) Prospektive multicenter trial on the short-term effects of plasmapheresis versus cytotoxic drugs in steroid resistent lupus nephritis. Neth J Med 33: 168–177Google Scholar

Schroeder JO, Euler HH, Loffler H (1987) Synchronization of plasmapheresis and pulse cyclophophamide in severe lupus erythematosus. Ann Intern Med 107: 344–346Google Scholar

Rook AH, Cohen JH, Lessin SR, Vowels BR (1993) Therapeutic applications of photopheresis. Dermatol Clin 11: 339–347Google Scholar

Zic J, Arzubiaga MD, Salhany KE, Parker RA, Wilson D, Stricklin GP, et al (1992) Extracorporal photopheresis for teh treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 27: 729–736Google Scholar

Knobler RM, Graninger W, Lindmaier A, Trautinger F (1991) Photophoresis for the treatment of systemic lupus erythematosus. Preliminary observations. Ann NY Acad Sci 636: 340–356Google Scholar

Ahmed SA, Penhale WJ, Talal N (1985) Sex hormones, immune responses, and autoimmune diseases: mechanisms of sex hormone action. Am J Pathol 121: 531–551Google Scholar

Lahita RG (1992) Sex, age and systemic lupus erythematosus. In: Lahita RG (ed) Systemic lupus erythematosus, 2nd edn. Churchill Livingstone, New York, pp 527–542Google Scholar

West SG, Johnson SC (1988) Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 108: 703–706Google Scholar

Jungers P, Kuttenen F, Liote F et al (1985) Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate. Arthritis Rheum 28: 1243–1250Google Scholar

Panayi GS, Kingsley GH, Lanchbury JSS (1992) Immunotherapy of immune-mediated diseases. Quart J Med 303: 489–495Google Scholar

Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Reithmüller G, Krüger K (1991) Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Arthritis Rheum 5: 525–536Google Scholar

Hiepe F, Volk HD, Apostoloff E, Baehr R von, Emmrich F (1991) Treatment of severe lupus erythematosus with anti-CD4 monoclonal antibody. Lancet 338: 1529–1530Google Scholar

Wacholtz M, Lipsky PE (1992) Treatment of lupus nephritis with CD5 plus, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain. Arthritis Rheum 35: 837–839Google Scholar

Schoenfeld Y, Isenburg D (1990) Treatment of autoimmune diseases. In: Schoenfeld Y, Isenburg D (eds) The mosaic of autoimmunity, Elsevier, Amsterdam, pp 455–507Google Scholar

Kingsley G, Panayi G, Lanchbury J (1991) Immunotherapy of rheumatic diseases — practice and prospects. Immunol Today 12: 177–179Google Scholar

Isaacs J, Watts RA, Hazelman BL, Hale G, Keogan MT, Cobbold SP, Waldman H (1992) Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 340: 748–752Google Scholar

Nicolas J-F, Thivolet J, Kanitakis J et al (1990) Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2A. J Invest Dermatol 95: 142S–145SGoogle Scholar

Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke OM, Kranzhoff M (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65: 70–74Google Scholar